Novo Nordisk A/S Stock
Novo Nordisk A/S
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- Denmark
- CEO
- Maziar Mike Doustdar
- Employees
- 68,794
- Market cap
- $171.4 B
- IPO
- 30/04/1981
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia, including Mainland China, Hong Kong, and…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Novo Nordisk A/S stock: price history
1D
-1.0%
1W
+0.5%
1M
-6.9%
6M
-4.2%
YTD
-23.7%
1Y
-30.8%
2Y
-67.1%
5Y
-24.1%
10Y
+91.5%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~88% stronger price swings than usual
Novo Nordisk A/S stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Ask the agents about Novo Nordisk A/S
Analyst assessment of Novo Nordisk A/S
PRICE TARGET LOW
US$40.00
CONSENSUS
US$42.33
MEDIAN
US$40.00
PRICE TARGET HIGH
US$47.00
1
STRONG BUY
22
BUY
13
HOLD
3
SELL
0
STRONG SELL
39
TOTAL · Buy
As of: 12/10/2026
Novo Nordisk A/S stock metrics
P/E
9.9
P/B
5.19
EV/EBITDA
6.99
RETURN ON EQUITY
9.5%
NET MARGIN
26.7%
DEBT/EQUITY
0.63
DIVIDEND YIELD
4.5%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
71.9%
FLOAT SHARES
3,173,014,289
AVG. DAILY VOLUME (30D)
13,340,342
Attention
4 mentions today in US forums, 300% more than yesterdayPrice since yesterday: -1.0%
Forums (Reddit)
See the full forum history with Pro.
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Novo Nordisk A/S stock
What does Novo Nordisk A/S do?
Novo Nordisk A/S is a company in the Healthcare sector, Drug Manufacturers - General industry, headquartered in Denmark.
The CEO is Maziar Mike Doustdar, the company employs around 68,794 people.
The IPO was on 30/04/1981; the stock trades on NYSE under the ticker NVO.
What do analysts say about Novo Nordisk A/S stock?
39 analysts rate the stock, the consensus is Buy (as of 12/10/2026).
The average price target is US$42.33, ranging from US$40.00 to US$47.00, with a median of US$40.00.
This is an external assessment, not a statement by Market Jury.
When does Novo Nordisk A/S report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 88% stronger than usual.
Does Novo Nordisk A/S pay a dividend?
Yes. The last dividend was US$0.58 per share, ex-date 17/08/2026, paid on 25/08/2026.
The dividend yield is 4.5% (as of 30/06/2026).
Which stocks are comparable to Novo Nordisk A/S?
Comparable stocks include Eli Lilly and Company, Johnson & Johnson, AbbVie, Merck &, Roche Holding, Amgen, Gilead Sciences and Pfizer.
How can I get Novo Nordisk A/S stock analyzed?
Clicking "Analyze stock" lets five strategies assess Novo Nordisk A/S against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.